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Abstract
Background: The aim of our study was to assess current practice patterns and attitudes towards diagnosis and
management of idiopathic pulmonary fibrosis (IPF) patients in Latin America.
Methods: A Cross-sectional survey was developed and up to 455 physicians were enrolled. We used a rigorous
method of validation using the translated version of the AIR Survey.
Results: Mean age was 47.5 years (SD 12.6) with 20.4 years (SD 12.3) of practice. In around 30% of physicians were
reported access to radiologist, pathologist and multidisciplinary team. Despite almost all physicians reported that
(ATS/ERS/JRS/ALAT) guidelines are useful, half of them prescribed corticoids for treatment of disease. Most
respondents (69.9%) reported cough as the presenting symptom. Around 80% considered IPF to be an important
clinical disorder, and felt that identifying patients at risk for IPF was important or extremely important. However,
only 59.7% felt confident in managing patients with IPF, and similar numbers (60.8%) felt confident about their
knowledge. Pulmonologist have more confidence and management of IPF that no pulmonologist.
Conclusion: The results of this survey of Latin American physicians could help to fill gaps regarding awareness,
management and treatment of IPF and improve earlier diagnosis of IPF.
Keywords: Idiopathic pulmonary fibrosis, Health knowledge, Attitudes, Practice, Surveys and questionnaires, Latin
America, Physicians
Background
Idiopathic Pulmonary Fibrosis (IPF) is characterised by
chronic, progressive and irreversible decline in pulmon-
ary function. Clinical symptoms and natural history are
unpredictable and vary in severity [1]. Because of the
complex nature and variable course of IPF, diagnosis and
treatment are difficult. New data have been published on
the safety and efficacy of treatments proposed to slow
the progression of the disease, to relieve symptoms, and
to improve quality of life [2, 3].
Using narrow case definitions, the annual incidence
of IPF in the US is estimated to be 6.8–8.8 per
100,000. IPF incidence increases with age and is
higher among males. In recent years the incidence ap-
pears to be increasing [4].
A retrospective longitudinal study suggested that
median survival of IPF patients is 3–5 years following
diagnosis [5].
Confirmation of the diagnosis requires exclusion of
other causes of interstitial lung disease (ILD), along with
the presence of the characteristic usual interstitial pneu-
monia (UIP) indicated by honeycombing on high reso-
lution computed tomography (HRCT). In those without
definitive radiological UIP, a surgical lung biopsy reveal-
ing characteristic findings of UIP is necessary for conclu-
sive diagnosis [6, 7].
The 2011 American Thoracic Society/ Japanese Re-
spiratory Society/ Latin American Thoracic Society
(ATS/ERS/JRS/ALAT) guidelines call for a multidiscip-
linary team (MDT) approach to IPF, in which
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information from several sources is combined and evalu-
ated [1]. MDT discussion is now considered the gold
standard for distinguishing IPF from other ILDs disease
[6]. In practice, MDT discussion may not always be pos-
sible [8]. Consequently, there is a degree of variability in
clinical practice among physicians, both in terms of
diagnosis and treatment of IPF [9].
A European survey of IPF management suggested
that physicians may benefit from periodic education
and update regarding IPF management [10]. In some
countries there is a lack of uniformity regarding the
diagnosis and management of IPF [11]. On the other
hand more of a half trainees physician felt that their
ILD training was inadequate [12].
In Latin America, where information is scarce, there is
a clear need to standardise the approach to diagnosis
and treatment of IPF patients.
The aim of our study was to assess current practice
patterns and attitudes towards diagnosis and manage-
ment of IPF patients in Latin America, to compare spe-




We conducted an anonymous cross-sectional survey, in
which physicians evaluated themselves regarding idio-
pathic pulmonary fibrosis. The original questionnaire
(AIR Survey, written in English) consisted of 28 ques-
tions relating to the clinical management of patients
with IPF [8]. We included questions designed to assess
physician attitude toward the disease. We used a rigor-
ous method of validation using the translated version of
the AIR Survey which we briefly described in the follow-
ing paragraph.
Two of the investigators translated the AIR survey to
Spanish. After that, the Spanish-language version was
translated to English by a third investigator who did not
know the original version of the AIR Survey. The back-
translated English-language version of the new Spanish-
language questionnaire was compared with the original
English-language version. Each item on the back-
translated English-language version was ranked by 30 in-
dividuals who were bilingual and independent of the
study team for comparability and similarity of interpret-
ability with the same item on the original English-
language version. Any translated item with a mean
score > 3 (seven was the worst agreement and one was
the best agreement) was formally reviewed and cor-
rected. The revised item was then translated back to
English and compared again with the original English-
language version of that item. This process continued
until the mean scores for each item indicated a valid ver-
sion (63 on each of the comparability and interpretability
rankings, and preferably <2.5 on the interpretability
rankings) [13].
Recruitment
The target population included physicians from Ecuador
and elsewhere in Latin America who attended the fol-
lowing meetings between November 2015 and October
2016: the VII-VIIIth International Meeting of Allergy
and Respiratory Medicine, Guayaquil, Ecuador; and the
XIIth Latin-American Expert Forum Santiago, Chile.
The inclusion criterion was having received a diploma as
a medical doctor. Potential candidates were asked if they
often managed patients with IPF. If they answered in the
affirmative, they were eligible for the study, and a self-
administered survey was delivered. This study was per-
formed in accordance with the Declaration of Helsinki.
This human study was approved by Comité de Ética en
Investigación en Seres Humanos - Clínica Kennedy. All
adult participants provided verbal consent to participate
in this study and this was approved by our IRB and was
because survey was anonymous and no interventions
were conducted. The verbal consent process was re-
corded/documented by the moment in which physician
completed the questionnaire.
Assessment
The first 28 questions of the AIR survey assessed the
current diagnostic and management of IPF, including
pharmacological therapy by physicians experienced in
IPF and management of comorbidities. Furthermore, we
included two “attitude questions” regarding the import-
ance of IPF as a clinical disorder and IPF diagnosis, and
three attitude questions regarding the physician’s confi-
dence in diagnosing, managing and knowledge about
IPF. These “attitudes and confidence questions” were
scored on a five-point Likert scale.
Statistical analysis
We used mean and standard deviation (SD) for age,
years of practice, and for number of patients with IPF
attended according to their age and forced vital capacity
(FVC). Percentages (%) were calculated for gender, na-
tionality, location of medical’s office, pulmonologist, ac-
cess to pathologist, radiologist, multidisciplinary team,
perception of IPF guidelines, risk factors and onset of
disease, treatment, monitoring progression of IPF and
managing comorbidities, and attitudes towards disease.
Attitudes towards disease were summarized as very im-
portant (very important and extremely important) and
very confident (agree and strongly agree). Mann-
Whitney U tests and chi square were used for compari-
sons among pulmonologists and non-pulmonologists
and number of patients with IPF attended according to
their age and FVC. Crude logistic analysis were
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performed among pulmonologists (non-pulmonologist
as reference category) and access to pathologist, radiolo-
gist, multidisciplinary team, perception of IPF guidelines,
risk factors and onset of disease, treatment, monitoring
progression of IPF and managing comorbidities, and at-
titudes towards disease. Statistical tests were performed
using SPSS version 13 (SPSS, Inc., Chicago, IL, 2000). A
p-value <0.05 was significant.
Results
Up to 455 physicians were enrolled. The majority were
male (55.4%). In total, 23.7% reported being a pulmonol-
ogist. Mean age was 47.5 years (SD 12.6) with 20.4 years
(SD 12.3) of practice.
Most physicians (74.7%, n = 340) reported having
cared for an IPF patient in previous year. Among
these physicians, 38.6% were female, attending in pri-
vate settings (48.4%), and one third (29.7%) were pul-
monologists. Most of participants were from Ecuador
(67.9%), followed by Chile (9.7%) and Peru (8.8%)
(Additional file 1: Table S1).
On average, 13.8 (SD 21.4) IPF patients were cared for
in the previous year. Physicians reported the highest
average number of IPF patients in the age group 66–
80 years old (3.6 patients, SD 12.1), with a forced vital
capacity (FVC) ranging from 50%–70% (3.3 patients, SD
9.8) (Table 1). Pulmonologist reported the highest num-
ber of IPF patients with a FVC ≥50% (p < 0.001).
Access to pathologists, radiologists and multidisciplinary
teams
Approximately one third of survey respondents reported
access to pathologists (27.8%), radiologists (39.4%), and
multidisciplinary teams (26.9%). Pulmonologists re-
ported greater access to radiologists (OR 1.59, CI 95%
0.91–2.78) and pathologists (OR 1.80, CI 95% 1.09–
2.96). Access to multidisciplinary teams was more com-
mon in pulmonologists (41.1% vs 20.8%) compared with
non-pulmonologists (p < 0.001).
Perception regarding IPF guidelines, risk factors and
disease onset
ATS/ERS 2011 guidelines were considered useful by al-
most all respondents (93.7%). No differences were found
among among physician specialties (OR 0.44, CI 95%
0.12–1.56). A total of 18.9% of respondents reported that
0–10% of their IPF patients smoke. Pulmonologists re-
ported higher rates of attending patients who smoking
(21.3% vs 17.8%, p < 0.05). Up to 49.5% were aware that
average time between symptom onset and diagnosis was
≤6 months, with no differences among specialties.
Almost one third (39.3%) of respondents reported that
their patients had visited one or two physicians prior to
diagnosis, with no differences among specialties.
Most respondents (69.9%) reported cough as the pre-
senting symptom. This result held with pulmonologists
and non-pulmonologists (OR 1.29, CI 95% 0.75–2.23),
and was similar among countries. In addition, dyspnoea
was frequently reported (54.6%), more often by pulmo-
nologists (OR 5.22, CI 95% 2.92–9.34)). “Velcro” breath
sounds were considered to be the first sign of IPF in
27.9% of respondents, more frequently in pulmonolo-
gists (OR 7.93, CI 95% 4.53–13.90).
Up to 92.8% of respondents reported obtaining family
history. In total, 97.9% inquired about occupation, while
18.4% pursued genetic causes. Up to 22.3% of respon-
dents reported managing mild and moderate IPF pa-
tients themselves, without collaboration. This finding
was more frequent among pulmonologists (35.0% vs
17.2%) (p < 0.001).
Regarding diagnosis and treatment of patients with
mild to moderate IPF, greater than 80% of physicians re-
ported that it was somewhat important (> 3 points) to
make and confirm the diagnosis, to manage comorbidi-
ties, to develop a monitoring plan, and to monitor effi-
cacy and tolerability of medication. Differences were not
found among physician specialties.
Treatment of IPF
Supplemental oxygen was prescribed most often (71.2%),
followed by corticosteroids alone (48.0%), N-acetylcysteine
Table 1 Comparisons among pulmonologist and non-pulmonologist physicians according to FVC value of IPF patients attended by
them
Amount of patients Pulmonologists
Yes
n = 91 (29.7%)
No
n = 215 (70.3%)
Total MW-U*
Mean SD Mean SD Mean SD p value
FVC < 50% 2.75 7.36 1.54 5.10 1.90 5.88 0.214
FVC 50%–70% 7.13 15.40 1.74 5.22 3.35 9.76 0.000
FVC 71%–80% 2.99 8.44 1.10 5.44 1.66 6.52 0.000
FVC > 80% 1.47 5.89 .63 4.67 .88 5.07 0.001
*MW-U: Mann–Whitney U test
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(NAC) alone (29.1%), and pirfenidone (17.0%). Higher
chances of supplemental oxygen prescription (OR 2.89; CI
95% 1.53–5.45) and pirfenidone (OR 10.29, CI 95% 5.20–
20.39) were observed in pulmonologists (Table 2). Partici-
pation in studies with pirfenidone were reported by 10.5%
of respondents, with higher chances among pulmonolo-
gists (OR 6.54, CI 95% 2.95–14.48) .
Monitoring progression of disease
The most common metrics for assessing progression of
disease were dyspnoea (63.7%), followed by FVC
(62.1%). Diffusing capacity (DLCO) was used less com-
monly (24.8%). Similarly, only 28.4% of respondents re-
ported using the 6-min-walk test (6MWT).
Pulmonologists reported higher chances of employing
for most of these tests (p < 0.001) (Table 3).
Managing comorbidities
In total, 64.1% of respondents reported always investigat-
ing for gastroesophageal reflux disease (GERD) (69.7% in
pulmonologists vs 61.7% in non-pulmonologists, p <
0.05). GERD was considered very important to manage
by 48.5% of respondents, but was treated systematically
by only 32.3% (37.8% by pulmonologists vs 29.8% by
non-pulmonologists). Non-pulmonologists considered
managing GERD as very important (55.6%) more fre-
quently than pulmonologists (45.3%).
Diet and lifestyle modifications were commonly rec-
ommended (75.7%), followed by proton pump inhibitors
(PPI) (69.3%) for treatment of GERD. PPI was more
commonly prescribed by pulmonologists (OR 2.67, CI
95% 1.45–4.90)). H2 blockers were prescribed by one
quarter of respondents (23.9%). This non-recommended
treatment was recommended more commonly by non-
pulmonologists (OR 0.53, CI 95% 0.28–1.00)).
The most frequent assessed comorbidity was cardio-
vascular disease (9.1%), followed by GERD (8.6%), and
lung cancer (7.4%). Lung cancer was assessed more fre-
quently among pulmonologists (10.0% vs 6.2%, p < 0.05).
Pulmonary Hypertension (PH) was treated in 55.0% of
patients. Sildenafil was used by half of respondents
(52.5%), more frequently by pulmonologists (OR 2.01, CI
95% 1.22–3.34)).
Attitudes about IPF
Among respondents that saw at least one IPF patient
per year, 77.2% considered IPF to be an important clin-
ical disorder, and 83.5% felt that identifying patients at
risk for IPF was important or extremely important. Of
these, 65.9% felt confident in identifying patients at risk
for IPF. However, only 59.7% felt confident in managing
patients with IPF, and similar numbers (60.8%) felt
confident about their knowledge (regarding diagnosis
and management) of IPF. Pulmonologists reported high-
est rates of importance and confidence (p < 0.001)
(Table 4).
Discussion
In our study, approximately one quarter of Latin Ameri-
can respondents reported access to a pathologist or a
multidisciplinary team in their professional network, as
compared with European participants (74% and 56%, re-
spectively). Meanwhile, European physicians reported
greater access to a radiologist (85%), in our continent
this access is only available in one third of physicians
[8]. In contrast, pulmonologist have more access to
Table 2 Comparisons among pulmonologist and non-pulmonologist physicians, according to progressionassessment of disease
Treatment Pulmonologist
Yes
N = 91 (29.7%)
No
N = 215 (70.3%)
Total
n % n % OR (CI 95%) n % p value*
Supplemental oxygen 77 84.6 141 65.6 2.89 (1.53–5.45) 218 71.2 0.001
Corticosteroids (CS) 39 42.9 108 50.2 0.74 (0.45–1.22) 147 48.0 0.238
Azatioprine 5 5.5 13 6.0 0.90 (0.31–2.61) 18 5.9 0.851
CS + immunosupressors (IS) 6 6.6 26 12.1 0.51 (0.20–1.29) 32 10.5 0.151
N-acetylcisteine (NAC) 30 33.0 59 27.4 1.30 (0.77–2.21) 89 29.1 0.331
Corticosteroids + NAC + IS 14 15.4 45 20.9 0.69 (0.36–1.33) 59 19.3 0.261
Corticosteroids + NAC 17 18.7 46 21.4 0.84 (0.45–1.57) 63 20.6 0.591
Colchicine 3 3.3 11 5.1 0.63 (0.17–2.32) 14 4.6 0.486
Ciclosporine 0 0.0 2 0.9 NS 2 0.7 0.356
Anti-blotting 1 1.1 15 7.0 0.15 (0.02–1.14) 16 5.2 0.035
Pirfenidona 38 41.8 14 6.5 10.29 (5.20–20.39) 52 17.0 0.000
Pirferidona + NAC 18 19.8 7 3.3 7.33 (2.94–18.25) 25 8.2 0.000
*Chi square
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pathologist, radiologist and multidisciplinary teams. Ap-
proximately 20% of respondents determine IPF manage-
ment on their own, compared with 7% reported in the
European survey [8].
Earlier diagnosis of IPF has become more relevant
since controlled clinical trials have demonstrated a re-
duction in the rate of decline of FVC [14, 15]. Almost
half of respondents reported that the average time be-
tween symptoms and diagnosis was ≤6 months, this re-
sult differs from European surveys in which the range
was 9–12 months. It is possible that our Latin-American
IPF patients were actually diagnosed earlier. Alterna-
tively, our result may reflect projection bias.
Our respondents reported that the most common pre-
senting symptom was cough (69.9%). This result was simi-
lar across specialties. This result differs from European
reports [8], because physician reported that dyspnoea was
the most common symptom (99%). However, pulmonolo-
gist reported more dyspnoea and that velcro breath
sounds were the first sign of IPF. All this could indicate
that pulmonologists have more clinical suspicion of IPF. It
is possible that our IPFß patients present with a different
IPF phenotype.
Our respondents reported that 22% of their patients
smoked, a substantially smaller percentage than reported
in the European survey (60%) [8]. This finding suggests
that there may be other risk factors associated with IPF
in our countries. Due to pulmonologists reported higher
rates of smoking, it could be possible that non-
pulmonologists attend patients with other causes of IPF.
Despite of our patients smoke less, they reported cough
as the primary onset symptom, and in general present
with more aggressive symptoms. Few physicians pursued
genetic causes, probably owing to the difficulty of per-
forming this kind of test in our countries.
Because IPF is a disease with a variable clinical course,
it is important to identify factors that may help predict
prognosis. Published guidelines recommended such tests
as FVC, DLCO and 6MWT [16, 17]. The high variability
associated with IPF makes predicting prognosis difficult,
and this in turn complicates treatment planning. Less
than one quarter of respondents employ DLCO and
6MWT, both of which could aid assessment and treat-
ment planning. Is known that physician have low confi-
dence interpreting result investigations in IPF [12]. In
our study, the pulmonologists reported higher chances
of usage for most of these tests.
Only 10% reported assessing GERD in IPF patients.
Half of respondents treated PH patients with sildenafil,
in contrast to the AIR survey, in which only a small
Table 3 Comparisons among pulmonologist and non-pulmonologist physicians, according to progression assessment of disease.
Progression assesment Pulmonologist
Yes
n = 91 (29.7%)
No
n = 215 (70.3%)
Total
n % n % OR (CI 95%) n % p value*
Dyspnea Scale 60 65.9 135 62.8 1.15 (0.69–1.92) 195 63.7 0.601
FVC lowering 75 82.4 115 53.5 4.08 (2.23–7.45) 190 62.1 0.000
DLCO lowering 50 54.9 26 12.1 8.87 (4.95–15.86) 76 24.8 0.000
CT 51 56.0 73 34.0 2.48 (1.50–4.09) 124 40.5 0.000
Exacerbation 28 30.8 65 30.2 1.03 (0.60–1.75) 93 30.4 0.926
6MWT 49 53.8 38 17.7 5.43 (3.16–9.33) 87 28.4 0.000
patient’s feedback 22 24.2 19 8.8 3.29 (1.68–6.44) 41 13.4 0.000
*Chi square test




N = 91 (29.7%)
No
N = 215 (70.3%)
Total
n % no % n % p value*
As a clinical disorder, IPF is important 76 86.4 148 73.3 224 77.2 0.014
IPF diagnosis is important 82 93.2 161 79.3 243 83.5 0.003
Confidence about diagnosing IPF 73 83.0 118 58.4 191 65.9 0.000
Confidence about maging IPF 68 77.3 105 52.0 173 59.7 0.000
Confidence about knowledge of IPF 69 78.4 106 53.0 175 60.8 0.000
*Chi square test
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proportion of respondents (4%) would regularly treat
PH. [8].
We predicted that IPF recommendations would be
followed by our respondent group because almost half
of participants reported they felt IPF guidelines were
useful. This was not necessarily the case. First, cortico-
steroids were frequently prescribed, in combination with
immunosuppressive therapy or NAC, contrary to guide-
lines. A similar discrepancy was found in an Australasian
study [11]. However, pulmonologist have higher rates of
supplemental oxygen prescription and use of
pirfenidone.
Approximately one third of respondents prescribed no
specific treatment for IPF, similar to the result found in
European surveys [3, 9]. Pirfenidone, a recommended
medication according to guidelines, was variably pre-
scribed, possibly because of limited availability in some
countries.
There are some disagreements between IPF guideline
recommendations and confidence in managing patients
with IPF. These discrepancies may reflect a degree of
self-protection among respondents.
Our results are comparable to the AIR study because
respondents manage IPF patients with similar levels of
severity [11]. Establishment of earlier diagnosis in both
studies suggests that we may be optimistic regarding the
future of IPF. Pulmonologists reported better confidence
and manage of IPF.
We suggest that optimal physician management of IPF
helps to identify factors that substantially affect patient
outcomes. Updated IPF guidelines in local languages
could lead to improved collaboration among primary
care physicians, pulmonologists, specialised centres,
pharmacists and other stakeholders involved in IPF
management.
Our study has several limitations. First, this was a
cross-sectional survey of physicians attending confer-
ences. Therefore, we cannot infer causation from any of
the associations we observed. We cannot generalise our
results to all Spanish-speaking physicians because med-
ical education regarding IPF might differ in other
Spanish-speaking countries in important ways. Further-
more we have few physician from other Latin-American
countries and we cannot generalize our result from all
Latinamerica. Physicians who travel to medical meetings
are likely to attend educational programs routinely, and
therefore these physicians might have access to more
updated medical knowledge than the larger group of
general practice physicians practicing in the community
who do not attend continuing medical education meet-
ings. Thus, management of IPF in the larger population
of general practice physicians and pulmonologists is
likely to be less optimal than was reported in our survey.
Furthermore, survey was self-administered with
subjective answers, that could reflect some protection
bias. Finally, our study didn’t include radiologists and
pathologist, who are members of MDT in diagnosis of
IPF.
The results of this survey of Latin American physicians
could help to fill gaps regarding awareness, management
and treatment of IPF especially in GP. Future studies are
needed to validate this survey in Latin America and other
Spanish-speaking physician populations. Also, IPF guide-
lines in clinical practice in Latin America could be imple-
mented according to clinical scenario in our region.
Incorporating IPF-focused educational interventions dur-
ing medical school and residency training programs could
help to improve management of the disease. Latin
American pulmonology societies could offer more IPF
sessions at continuing medical education conferences.
They could also create IPF education programs for general
physicians such as those that currently exist for asthma
and chronic obstructive pulmonary disease.
Conclusions
Despite high rates of awareness of international IPF
guidelines, most IPF recommendations are not followed.
To achieve better outcomes for our patients, we recom-
mend improving IPF education in Latin America. Better
knowledge of the disease and improved skills in generat-
ing a differential diagnosis may contribute to earlier
diagnosis and treatment of IPF.
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